Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd, together with its subsidiaries, engages in the pharmaceutical manufacturing and drug distribution businesses in China. The company produces and sells medicines and related health care products, including tablets, granules, pills, mixtures, oral liquids, syrups, eye drops, pills, soft capsules, tablets, hard capsules, and other health foods. I… Read more
Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd (600671) - Total Liabilities
Latest total liabilities as of September 2025: CN¥335.43 Million CNY
Based on the latest financial reports, Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd (600671) has total liabilities worth CN¥335.43 Million CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd - Total Liabilities Trend (1993–2024)
This chart illustrates how Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd Competitors by Total Liabilities
The table below lists competitors of Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Clasquin
PA:ALCLA
|
France | €203.60 Million |
|
Mokingran Jewellery Group Co., Ltd.
F:0HY
|
Germany | €2.84 Billion |
|
lastminute.com N.V
PINK:LSMNF
|
USA | $424.30 Million |
|
United Pharm
KO:033270
|
Korea | ₩64.04 Billion |
|
Journey Medical Corp
NASDAQ:DERM
|
USA | $59.29 Million |
|
Cool Company Oy
OL:CLCO
|
Norway | Nkr1.53 Billion |
|
Angel Oak Mortgage Inc
NYSE:AOMR
|
USA | $2.48 Billion |
Liability Composition Analysis (1993–2024)
This chart breaks down Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.81 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 5.04 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.78 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd (1993–2024)
The table below shows the annual total liabilities of Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd from 1993 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥356.44 Million | +22.77% |
| 2023-12-31 | CN¥290.34 Million | -1.70% |
| 2022-12-31 | CN¥295.36 Million | -12.64% |
| 2021-12-31 | CN¥338.09 Million | -3.18% |
| 2020-12-31 | CN¥349.18 Million | -11.29% |
| 2019-12-31 | CN¥393.60 Million | -1.35% |
| 2018-12-31 | CN¥398.99 Million | +12.65% |
| 2017-12-31 | CN¥354.18 Million | +47.57% |
| 2016-12-31 | CN¥240.01 Million | +10.29% |
| 2015-12-31 | CN¥217.63 Million | +8.60% |
| 2014-12-31 | CN¥200.40 Million | -12.87% |
| 2013-12-31 | CN¥230.01 Million | +13.21% |
| 2012-12-31 | CN¥203.17 Million | +16.09% |
| 2011-12-31 | CN¥175.00 Million | +5.64% |
| 2010-12-31 | CN¥165.66 Million | +17.88% |
| 2009-12-31 | CN¥140.53 Million | +9.12% |
| 2008-12-31 | CN¥128.78 Million | -1.81% |
| 2007-12-31 | CN¥131.16 Million | +13.03% |
| 2006-12-31 | CN¥116.04 Million | -12.97% |
| 2005-12-31 | CN¥133.32 Million | +26.38% |
| 2004-12-31 | CN¥105.49 Million | +1.56% |
| 2003-12-31 | CN¥103.88 Million | -13.67% |
| 2002-12-31 | CN¥120.32 Million | -23.42% |
| 2001-12-31 | CN¥157.11 Million | +1.63% |
| 2000-12-31 | CN¥154.60 Million | +61.58% |
| 1999-12-31 | CN¥95.68 Million | +9.59% |
| 1998-12-31 | CN¥87.30 Million | +23.94% |
| 1997-12-31 | CN¥70.44 Million | +21.83% |
| 1996-12-31 | CN¥57.82 Million | -35.04% |
| 1995-12-31 | CN¥89.00 Million | -53.67% |
| 1994-12-31 | CN¥192.12 Million | +610.98% |
| 1993-12-31 | CN¥27.02 Million | -- |